Neuren Pharmaceuticals Limited (ASX: NEU)
Australia
· Delayed Price · Currency is AUD 12.43
-1.26 (-9.20%)
Nov 21, 2024, 4:10 PM AEST
Neuren Pharmaceuticals Income Statement
Financials in millions AUD. Fiscal year is January - December.
Millions AUD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 193.33 | 231.93 | 14.55 | - | 0.72 | 0.5 | Upgrade
|
| Other Revenue | 0.02 | 0.02 | 0.86 | 3.2 | - | - | Upgrade
|
| Revenue | 193.34 | 231.94 | 15.42 | 3.2 | 0.72 | 0.5 | Upgrade
|
| Revenue Growth (YoY) | 146.79% | 1404.46% | 382.23% | 345.89% | 44.85% | -96.46% | Upgrade
|
| Cost of Revenue | 32.9 | 26.75 | 12.71 | 9.52 | 7.76 | 9.86 | Upgrade
|
| Gross Profit | 160.44 | 205.19 | 2.71 | -6.32 | -7.05 | -9.36 | Upgrade
|
| Selling, General & Admin | 5.28 | 5.95 | 3.44 | 1.91 | 1.76 | 1.71 | Upgrade
|
| Operating Expenses | 5.28 | 5.95 | 3.44 | 1.91 | 1.76 | 1.71 | Upgrade
|
| Operating Income | 155.17 | 199.25 | -0.73 | -8.23 | -8.81 | -11.08 | Upgrade
|
| Interest & Investment Income | 10.84 | 5.69 | 0.39 | 0.04 | 0.15 | 0.39 | Upgrade
|
| Currency Exchange Gain (Loss) | 1.79 | 2.43 | 1.23 | 0.4 | -0.63 | 0.13 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.44 | -2.23 | -0.7 | - | 0.1 | - | Upgrade
|
| EBT Excluding Unusual Items | 167.36 | 205.14 | 0.18 | -7.79 | -9.19 | -10.56 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | -0.26 | Upgrade
|
| Pretax Income | 167.36 | 205.14 | 0.18 | -7.79 | -9.19 | -10.82 | Upgrade
|
| Income Tax Expense | 50.07 | 48.06 | - | - | - | - | Upgrade
|
| Earnings From Continuing Operations | 117.29 | 157.08 | 0.18 | -7.79 | -9.19 | -10.82 | Upgrade
|
| Net Income | 117.29 | 157.08 | 0.18 | -7.79 | -9.19 | -10.82 | Upgrade
|
| Net Income to Common | 117.29 | 157.08 | 0.18 | -7.79 | -9.19 | -10.82 | Upgrade
|
| Net Income Growth | 113.09% | 85270.11% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 128 | 127 | 126 | 118 | 107 | 100 | Upgrade
|
| Shares Outstanding (Diluted) | 131 | 131 | 129 | 119 | 107 | 100 | Upgrade
|
| Shares Change (YoY) | 0.15% | 1.44% | 8.76% | 10.71% | 6.88% | 0.42% | Upgrade
|
| EPS (Basic) | 0.92 | 1.24 | 0.00 | -0.07 | -0.09 | -0.11 | Upgrade
|
| EPS (Diluted) | 0.89 | 1.20 | 0.00 | -0.07 | -0.09 | -0.11 | Upgrade
|
| EPS Growth | 112.92% | 120000.00% | - | - | - | - | Upgrade
|
| Free Cash Flow | 119.49 | 184.89 | 3.58 | -9.98 | -8.08 | -11.73 | Upgrade
|
| Free Cash Flow Per Share | 0.91 | 1.41 | 0.03 | -0.08 | -0.08 | -0.12 | Upgrade
|
| Gross Margin | 82.98% | 88.47% | 17.55% | -197.65% | - | - | Upgrade
|
| Operating Margin | 80.25% | 85.90% | -4.75% | -257.52% | -1228.59% | -2237.58% | Upgrade
|
| Profit Margin | 60.67% | 67.72% | 1.19% | -243.79% | -1282.15% | -2185.05% | Upgrade
|
| Free Cash Flow Margin | 61.80% | 79.71% | 23.22% | -312.17% | -1127.48% | -2369.90% | Upgrade
|
| EBITDA | 155.19 | 199.26 | -0.72 | -8.23 | -8.8 | -11.07 | Upgrade
|
| EBITDA Margin | 80.27% | 85.91% | -4.68% | -257.27% | - | - | Upgrade
|
| D&A For EBITDA | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0 | Upgrade
|
| EBIT | 155.17 | 199.25 | -0.73 | -8.23 | -8.81 | -11.08 | Upgrade
|
| EBIT Margin | 80.25% | 85.90% | -4.75% | -257.52% | - | - | Upgrade
|
| Effective Tax Rate | 29.92% | 23.43% | - | - | - | - | Upgrade
|
| Revenue as Reported | 207.76 | 240.06 | 17.03 | 3.64 | 0.96 | 1.02 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.